Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Walking Fish Therapeutics, Inc..
Walking Fish Therapeutics, Inc. is a company.
Key people at Walking Fish Therapeutics, Inc..
Key people at Walking Fish Therapeutics, Inc..
Walking Fish Therapeutics, Inc. was a biotechnology company that engineered B cells to act as protein factories for treating serious diseases including cancer, autoimmune disorders, regenerative medicine needs, and rare diseases like Fabry disease.[1][2][3] It targeted oncology (e.g., solid tumors), autoimmune conditions, infectious diseases, and deficiencies by developing cell-based therapies such as WFT-1, WFT-2, and WFX-003, all in preclinical stages before shutdown.[1][3][5] The company raised $73 million across two Series A rounds ($50M in 2021, $23M in 2022) but ceased operations in May 2024 after a lead investor withdrew from a planned Series B, just as it sought clinical trial clearance for its Fabry program.[1]
Headquartered in South San Francisco, California, Walking Fish served patients with unmet needs in immuno-oncology and regenerative medicine, drawing inspiration from the axolotl's regenerative abilities to create potent, tissue-targeted B cell therapies.[2][3] Despite early momentum with an oversubscribed Series A and lab expansion, the firm shut down abruptly, auctioning equipment shortly after.[1]
Founded in 2019 (some sources note 2018), Walking Fish Therapeutics emerged from alumni of Five Prime Therapeutics, led by CEO Rusty Williams, MD, PhD.[1][2][4] Williams, with expertise in protein therapeutics and immuno-oncology, drove the vision for B cell engineering as a novel cell therapy modality.[3][4] The idea built on deep B cell biology knowledge to transform these cells into long-lasting protein and antibody factories, inspired by natural regenerative processes like those in the axolotl.[3]
Early traction included a $50M Series A in September 2021, followed by a $23M extension in February 2022, enabling a new 22,000 sq ft headquarters and lab in South San Francisco.[1][2] The team expanded leadership, appointing Georgia Erbez as COO, and advanced a pipeline toward clinical trials in oncology, rare diseases, and regenerative medicine.[2] Pivotal moments included platform advancements and preclinical candidates like WFX-001 for Fabry disease.[1][5]
Walking Fish rode the wave of next-generation cell therapies, shifting from T cell-focused CAR-T to B cell engineering for more persistent, tunable protein delivery in oncology and regeneration.[1][3] Timing aligned with surging biotech investment in immuno-oncology and rare diseases post-2020, fueled by mRNA successes and demand for targeted biologics amid autoimmune epidemics.[1][2] Market forces like high unmet needs in solid tumors and Fabry disease favored its platform, which promised localized responses without broad toxicity.[3][5]
Though short-lived, it influenced the ecosystem by validating B cells as a modality—paving for competitors like Immusoft—and highlighting funding risks in preclinical biotech, where investor pullouts can end promising ventures.[1] Its auction and IP potential underscore asset recycling in a consolidating sector.
Walking Fish's shutdown in May 2024 marks a cautionary tale of biotech volatility: strong science and $73M raised couldn't overcome Series B hurdles amid a cooling funding climate.[1] Its B cell platform assets, including preclinical candidates, were likely acquired post-auction, potentially fueling ongoing efforts in oncology and rare diseases by acquirers or rivals.[1][5]
Trends like AI-driven protein design and combination cell therapies will shape successors, amplifying B cell potential for durable, off-the-shelf treatments. Walking Fish's legacy endures in proving the concept, reminding investors that timing and partnerships define survival in high-stakes biotech.
